Dr. Shields is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
840 Walnut St
Ste 1440
Philadelphia, PA 19107Phone+1 215-928-3105Fax+1 215-928-1140
Summary
- Carol Shields, MD, is an ophthalmologist based in Philadelphia, PA, specializing in pediatric and adult ocular oncology. She completed her medical education at the University of Pittsburgh School of Medicine, followed by a residency in ophthalmology at Wills Eye Hospital and 3 fellowships in ophthalmic pathology at Wills Eye, ocular oncology at Wills Eye, and oculoplastics surgical observership at Moorfields Eye Hospital in London England. Since 1988, she has served as an attending surgeon at Wills Eye Hospital and is now a Professor of Ophthalmology. Her expertise includes brachytherapy for uveal melanoma, retinoblastoma management, and other conjunctival, intraocular, and orbital tumors. Dr. Shields has published extensively on topics such as molecular genetics in melanoma and is involved in several clinical trials related to ocular melanoma and retinoblastoma. She has received numerous accolades, including America's Top Doctors and America's Top Doctors for Cancer from Castle Connolly, and is a Fellow of the American Academy of Ophthalmology.
Education & Training
- Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Hematology and Medical Oncology, 1988 - 1989
- Sidney Kimmel Medical College at Thomas Jefferson University/Wills Eye HospitalResidency, Ophthalmology, 1984 - 1988
- Sidney Kimmel Medical College at Thomas Jefferson University/Wills Eye HospitalResidency, Ophthalmology, 1984 - 1987
- UPMC Medical Education (Mercy)Internship, Transitional Year, 1983 - 1984
- University of Pittsburgh School of MedicineClass of 1983
Certifications & Licensure
- DC State Medical License Current
- DE State Medical License Current
- NY State Medical License 1995 - 2026
- PA State Medical License 1984 - 2026
- NJ State Medical License 1985 - 2025
- MD State Medical License 2018 - 2023
- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2007-2014
- Philadelphia Magazine Castle Connolly, 2005-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- Sub-Tenon Triamcinolone in the Prevention of Radiation-Induced Macular Edema Start of enrollment: 2004 Nov 01
- Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Start of enrollment: 2007 Apr 01
- A Study of the Effectiveness of a Local Injection of Chemotherapy for Retinoblastoma Start of enrollment: 2009 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- The Association Between Medical Insurance, Access to Care, and Outcomes for Patients with Uveal Melanoma in the United States.Victoria A Marks, Basil K Williams Jr, Michael S Leapman, Carol L Shields
Seminars in Ophthalmology. 2025-04-01 - Caruncular Dacryops Arising from Lacrimal Gland of Popoff.Matthew E Wei, Tatyana Milman, Carol L Shields
Ophthalmology. 2025-03-20 - "Safety Assessment of Aqueous Humor Liquid Biopsy in Retinoblastoma: A Multicenter Study of 1,203 Procedures".Douglas Chigane, Drishti Pandya, Muskaan Singh, Brianne Brown, Michelle Lin
Ophthalmology. 2025-03-19
Journal Articles
- Visual Outcome and Millimeter Incremental Risk of Metastasis in 1780 Patients with Small Choroidal Melanoma Managed by Plaque RadiotherapyLydia Komarnicky, Arman Mashayekhi, Carol L Shields, Laura E Barna, Jerry A Shields, JAMA
- Comparison of Posterior Lamellar Resection Versus Lumpectomy for Initial Management of Localized Tarsal Conjunctival Sebaceous Carcinoma in 54 CasesJerry A Shields, Carol L Shields, Sara E Lally, Indian Journal of Ophthalmology
Press Mentions
- Aura Biosciences Reports Third Quarter 2024 Financial Results and Business HighlightsNovember 12th, 2024
- Aura Biosciences Reports Third Quarter 2024 Financial Results and Business HighlightsNovember 12th, 2024
- Three Cycles of Chemo Noninferior to Six for Rare Childhood Eye CancerOctober 21st, 2024
- Join now to see all
Professional Memberships
- Fellow
External Links
- http://www.fighteyecancer.comhttp://www.fighteyecancer.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: